Expression of small nucleolar RNA SNORA51 and its clinical significance in hepatocellular carcinoma

Yu,Liang; Zhang,Mei; Ma,Zhenhua; Wu,Shengli

doi:10.3892/ol.2023.14188

Expression of small nucleolar RNA SNORA51 and its clinical significance in hepatocellular carcinoma

Authors:
- Liang Yu
- Mei Zhang
- Zhenhua Ma
- Shengli Wu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: December 12, 2023 https://doi.org/10.3892/ol.2023.14188
Article Number: 55

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small nucleolar RNA H/ACA Box 51 (SNORA51) is involved in progression of multiple cancers. However, its role in hepatocellular carcinoma (HCC) is still unclear. The aim of the present study was to analyze the expression of SNORA51 in HCC and its clinical significance. A total of 136 patients with HCC who underwent surgery from January 1, 2016 to December 31, 2018 were included. The expression of SNORA51 in cancer tissues and adjacent tissues was compared using reverse transcription‑quantitative PCR and bioinformatics methods. Methylation of the SNORA51 promoter in cancer and adjacent tissues was compared using bioinformatics. The relationship between SNORA51 expression levels and clinicopathological characteristics of patients with HCC, in addition to prognosis, was analyzed. The expression of SNORA51 in HCC was significantly higher compared with that in adjacent tissues (P<0.05). starBase demonstrated that higher expression levels of SNORA51 were associated with a significantly worse prognosis of patients with HCC compared with those who had lower expression levels of SNORA51 (P<0.05). Bioinformatics analysis using The University of Alabama at Birmingham Cancer Data Analysis Portal demonstrated that methylation of the SNORA51 promoter region in HCC was significantly decreased compared with adjacent tissues (P<0.05). A high expression of SNORA51 was significantly associated with portal vein tumor thrombus, vascular invasion and TNM stage (P<0.05). The median survival time of patients with high SNORA51 expression was significantly lower compared with those who had low SNORA51 expression (P<0.05). Both uni‑ and multivariate Cox regression analysis demonstrated that SNORA51 expression was an independent risk factor that significantly worsened the prognosis of patients with HCC (P<0.05). The overexpression of SNORA51 in patients with HCC was significantly associated with a poor prognosis and may be related to the reduced methylation of the SNORA51 promoter region. Therefore, SNORA51 may be a promising biomarker for prediction of the prognosis of patients with HCC and may be a therapeutic target for the treatment of HCC in future.

View Figures

View References

1	Chakraborty E and Sarkar D: Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel). 14:27982022. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Teo EK and Fock KM: Hepatocellular carcinoma: An Asian perspective. Dig Dis. 19:263–268. 2001. View Article : Google Scholar : PubMed/NCBI
4	Orcutt ST and Anaya DA: Liver resection and surgical strategies for management of primary liver cancer. Cancer Control. 25:10732748177446212018. View Article : Google Scholar : PubMed/NCBI
5	Anwanwan D, Singh SK, Singh S, Saikam V and Singh R: Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020. View Article : Google Scholar : PubMed/NCBI
6	Kufel J and Grzechnik P: Small nucleolar RNAs tell a different tale. Trends Genet. 35:104–117. 2019. View Article : Google Scholar : PubMed/NCBI
7	Zhang Z, Yu H, Yao W, Zhu N, Miao R, Liu Z, Song X, Xue C, Cai C, Cheng M, et al: RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway. Cell Commun Signal. 20:1882022. View Article : Google Scholar : PubMed/NCBI
8	Pecoraro A, Pagano M, Russo G and Russo A: Ribosome biogenesis and cancer: Overview on ribosomal proteins. Int J Mol Sci. 22:54962021. View Article : Google Scholar : PubMed/NCBI
9	Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, et al: The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer. 104:1168–1177. 2011. View Article : Google Scholar : PubMed/NCBI
10	Yang X, Li Y, Li L, Liu J, Wu M and Ye M: SnoRNAs are involved in the progression of ulcerative colitis and colorectal cancer. Dig Liver Dis. 49:545–551. 2017. View Article : Google Scholar : PubMed/NCBI
11	Cui L, Nakano K, Obchoei S, Setoguchi K, Matsumoto M, Yamamoto T, Obika S, Shimada K and Hiraoka N: Small nucleolar noncoding RNA SNORA23, up-regulated in human pancreatic ductal adenocarcinoma, regulates expression of spectrin repeat-containing nuclear envelope 2 to promote growth and metastasis of xenograft tumors in mice. Gastroenterology. 153:292–306. 2017. View Article : Google Scholar : PubMed/NCBI
12	Domingo-Relloso A, Huan T, Haack K, Riffo-Campos AL, Levy D, Fallin MD, Terry MB, Zhang Y, Rhoades DA, Herreros-Martinez M, et al: DNA methylation and cancer incidence: Lymphatic-hematopoietic versus solid cancers in the Strong Heart Study. Clin Epigenetics. 13:432021. View Article : Google Scholar : PubMed/NCBI
13	Zheng J, Zhang T, Guo W, Zhou C, Cui X, Gao L, Cai C and Xu Y: Integrative analysis of Multi-Omics identified the prognostic biomarkers in acute myelogenous leukemia. Front Oncol. 10:5919372020. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Jensen MA and Zenklusen JC: A practical guide to the cancer genome atlas (TCGA). Methods Mol Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kumar AR, L A, Nair B, Mathew B, Sugunan S and Nath LR: Decoding the Mechanism of drugs of heterocyclic nature against hepatocellular carcinoma. Anticancer Agents Med Chem. 23:882–893. 2023. View Article : Google Scholar : PubMed/NCBI
17	Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, et al: HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 77:128–139. 2022. View Article : Google Scholar : PubMed/NCBI
18	Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, et al: Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines. Eur J Radiol. 101:72–81. 2018. View Article : Google Scholar : PubMed/NCBI
19	Chen CL, Chen CJ, Vallon O, Huang ZP, Zhou H and Qu LH: Genomewide analysis of box C/D and box H/ACA snoRNAs in Chlamydomonas reinhardtii reveals an extensive organization into intronic gene clusters. Genetics. 179:21–30. 2008. View Article : Google Scholar : PubMed/NCBI
20	Romano G, Veneziano D, Acunzo M and Croce CM: Small non-coding RNA and cancer. Carcinogenesis. 38:485–491. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang D, Zhou J, Gao J, Wu RY, Huang YL, Jin QW, Chen JS, Tang WZ and Yan LH: Targeting snoRNAs as an emerging method of therapeutic development for cancer. Am J Cancer Res. 9:1504–1516. 2019.PubMed/NCBI
22	Yi C, Wan X, Zhang Y, Fu F, Zhao C, Qin R, Wu H, Li Y and Huang Y: SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis. Int J Biochem Cell Biol. 102:138–150. 2018. View Article : Google Scholar : PubMed/NCBI
23	Okugawa Y, Toiyama Y, Toden S, Mitoma H, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut. 66:107–117. 2017. View Article : Google Scholar : PubMed/NCBI
24	Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W and Dong JT: Implication of snoRNA U50 in human breast cancer. J Genet Genomics. 36:447–454. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wan R, Bai L, Cai C, Ya W, Jiang J, Hu C, Chen Q, Zhao B and Li Y: Discovery of tumor immune infiltration-related snoRNAs for predicting tumor immune microenvironment status and prognosis in lung adenocarcinoma. Comput Struct Biotechnol J. 19:6386–6399. 2021. View Article : Google Scholar : PubMed/NCBI
26	Łuczkowska K, Kulig P, Baumert B and Machaliński B: The evidence that 25(OH)D3 and VK2 MK-7 vitamins influence the proliferative potential and gene expression profiles of multiple myeloma cells and the development of resistance to bortezomib. Nutrients. 14:51902022. View Article : Google Scholar : PubMed/NCBI
27	Liang F, Qu H, Lin Q, Yang Y, Ruan X, Zhang B, Liu Y, Yu C, Zhang H, Fang X and Hao X: Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes. World J Surg Oncol. 13:2582015. View Article : Google Scholar : PubMed/NCBI
28	Tosar JP, García-Silva MR and Cayota A: Circulating SNORD57 rather than piR-54265 is a promising biomarker for colorectal cancer: Common pitfalls in the study of somatic piRNAs in cancer. RNA. 27:403–410. 2021. View Article : Google Scholar : PubMed/NCBI
29	Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W and Wang C: Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
30	Wang L, Mo H, Jiang Y, Wang Y, Sun L, Yao B, Chen T, Liu R, Li Q, Liu Q and Yin G: MicroRNA-519c-3p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting BTG3. Biomed Pharmacother. 118:1092672019. View Article : Google Scholar : PubMed/NCBI